100 - Primary Outcome Analysis for Shortening Adjuvant Photon Irradiation to Reduce Edema (SAPHIRE): A Randomized, Phase III Trial of Hypo- vs. Conventionally Fractionated Regional Nodal Irradiation (RNI)
101 - Long Term Rates of Lymphedema in Hypofractionated Nodal Regional Irradiation for Women with Breast Cancer: A Phase 2 Clinical Trial - "HeNRIetta"
Location: Room 202
Presenter: Alfredo Urdaneta, MD – Virginia Commonwealth University Health System
8:20 AM – 8:30 AM ET
102 - NOVEMBER, A Phase II Trial of a 9 Day Course of Whole Breast Radiotherapy for Early Stage Breast Cancer
103 - Early Safety of Ultra-Hypofractionated Whole Breast Irradiation and Sequential Tumor Bed Boost for Early Breast Cancer (SHIFT): A Multicenter, Phase 2 Trial
Location: Room 202
Presenter: Siyue Zheng, MD – Ruijin Hospital, Shanghai Jiaotong University School of Medicine
8:40 AM – 8:50 AM ET
104 - Conventional vs. Hypofractionated Proton Postmastectomy Radiotherapy: Patient Reported Outcomes from a Randomized Phase 2 Trial
107 - Moderated Hypofractionated Online Adaptive Radiotherapy in Locally Advanced Cervical Cancer: A Prospective 1 Clinical Trial
Location: Room 204
Presenter: Zheng Zeng, MD – Peking Union Medical College Hospital
8:30 AM – 8:40 AM ET
108 - Acceleration of Overall Treatment Time by Mono-Application Multifractionated Brachytherapy over 48 Hours vs. Sequential Weekly Application Brachytherapy in Carcinoma Cervix - Multi-Institutional, Subc
109 - Image Guided Brachytherapy Quality Assurance on NRG GY017, an NRG Oncology Clinical Trial Investigating the Sequencing of Immunotherapy and Chemoradiation for Locally Advanced Cervical Cancer
Location: Room 204
Presenter: Hayeon Kim, PhD – Magee Womens Hospital of University of Pittsburgh Medical Center and Hillman Cancer Center
8:50 AM – 9:00 AM ET
Discussant
Location: Room 204
Discussant: Scott Glaser, MD – City of Hope National Medical Center
8:00 AM – 8:10 AM ET
110 - Clinical Outcomes for Standard of Care Machine Learning Prostate Radiotherapy Treatment Planning
111 - DeepTuning: A Novel Deep Learning Approach for Interactive Plan Tuning and Trade-Off Exploration
Location: Room 147
Presenter: Lin Ma, PhD – Mayo Clinic College of Medicine and Science Rochester
8:20 AM – 8:30 AM ET
112 - Initial Clinical Experience of Cherenkov Imaging in Sub-Total Total Skin Electron Therapy Identifies Opportunities to Improve Daily Set-Up QA
Location: Room 147
Presenter: Brook Byrd, PhD, MS, BS – Penn Medicine Radiation Oncology Abramson Cancer Center
8:30 AM – 8:40 AM ET
113 - Individual Radiotherapy Plan Based on Multi-Omics Model Study for Cervical Cancer Patients with Ovarian Preservation
Location: Room 147
Presenter: Guang Li, PhD – Chongqing University Cancer Hospital
8:40 AM – 8:50 AM ET
114 - Results of a Dose Reconstruction Effort for a Large-Scale Retrospective Study on Late Health Effects Following Radiotherapy within the National Wilms Tumor Study
1000 - Impact of Prior Local Therapy (LT) on Treatment Response and Survival of Men with Metastatic Castrate Resistant Prostate Cancer (mCRPC): A Pooled Analysis of COU-AA-302 and ACIS Trials
Location: Room 207 B
Presenter: Omar Azem, MD – Rush University Medical Center
8:10 AM – 8:15 AM ET
1001 - Post-Prostatectomy Linac-Based Ultrahypofractionated Radiotherapy for Patients with Localized Prostate Cancer: Toxicity and Quality-of Life Results from a Prospective Trial
1002 - Radiotherapy of the Primary Tumor and All Metastatic Lesions in Oligometastatic Prostate Cancer: 5-Year Results of Prolong Study
Location: Room 207 B
Presenter: Xin Qi, MD, MS – Peking University First Hospital
8:20 AM – 8:25 AM ET
1003 - Initial Results of a Phase 2 Trial of Stereotactic Body Radiation Therapy, Hormone/Androgen Deprivation Therapy and Radium 223 Dichloride for Oligometastatic Castrate Sensitive Prostate Cancer (SHARP)
1004 - Stereotactic Body Radiation Therapy (SBRT) Combined with Pelvic Radiotherapy and GTV Boost Based on Multiparameter Magnetic Resonance Image for High-Risk Prostate Cancer: A Phase II Study
1005 - A Prospective Pilot Study Investigating 18F rhPSMA-7.3 PET/MRI to Detect Recurrent Disease and Guide Radiotherapy Planning in Patients with Biochemically Recurrent Prostate Cancer Post-Pros
2 - A Prospective, Phase II Study of 177Lu-Dotatate in Patients with Surgery- and Radiation-Refractory Meningioma: Results of the WHO Grade II/III Cohort
3 - A Phase 3 Study of Pembrolizumab (Pembro) + Concurrent Chemoradiotherapy (CCRT) for High-Risk Locally Advanced Cervical Cancer (LACC): Safety Findings
4 - Hypofractionated Whole-Breast Irradiation with Simultaneous Integrated Boost for Breast Cancer: Primary Analysis of the HYPOSIB-Trial (ARO 2013-05)
Location: Ballroom A/B/C
Presenter: David Krug, MD – University Hospital Hamburg-Eppendorf
LBA06 - Short-Term Androgen Deprivation Therapy and High-Dose Radiotherapy in Intermediate- and High-Risk Localized Prostate Cancer: Results from the GETUG 14 Randomized Phase III Trial
LBA07 - A Multicenter Phase III Randomized Clinical Trial Comparing the Efficacy of an Adjuvant SOX Chemotherapy Regimen with SOX Combined with a Simultaneous Radiotherapy Regimen after D2 Radical Resection f
Location: Ballroom A/B/C
Presenter: Ou-ying Yan, MD – Cancer Center, West China Hospital, Sichuan University
2:45 PM – 2:55 PM ET
130 - MORF4L1-Mediated DNA Damage Repair Modulates cGAS-STING Activation and Radiosensitivity in Hepatocellular Carcinoma
Location: Room 152
Presenter: Siwei Wang, PhD – Department of Radiation Oncology, Cancer Center, Zhongshan Hospital, Fudan University
2:55 PM – 3:05 PM ET
131 - Unraveling the Mechanism behind Prophylactic Radiotherapy to Prevent Traumatic Heterotopic Ossification
1007 - Efficacy of Quantitative Targeted Exercise Combined with Full-Scale Refined Nutrition Management for Improving Nutrition in Patients with Head and Neck Cancer Receiving Radiotherapy - A Randomized Con
Location: Room 158
Presenter: Juanli Shi – Xijing Hospital Air Force Medical University
3:00 PM – 3:05 PM ET
1008 - The HEART Team Protocol: A Strategic Approach to High-Risk Patient Management in Adult Oncology to Reduce Emergency Room Visits and Hospital Admissions
1009 - Efficacy and Safety of a Dexamethasone-Free Antiemetic Regimen for Nausea and Emesis Prevention during Concurrent Chemoradiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC
1010 - Development of a Program Utilizing the Simple Measure of Gobbledygook (SMOG) Algorithm for Comprehending Patient-Generated Educational Content in the Field of Radiation Oncology
138 - The Prognostic Value of Pretreatment Carbohydrate Antigen 125 Level in Cervical Cancer Patients Treated with Definitive Radiotherapy or Concurrent Chemoradiotherapy
Location: Room 207 B
Presenter: Dingchao Liu, MD – Peking Union Medical College Hospital
3:15 PM – 3:25 PM ET
139 - Longitudinal Dynamic MRI Radiomic Models for Early Prediction of Prognosis in Locally Advanced Cervical Cancer Treated with Concurrent Chemoradiotherapy
141 - Effect of Cisplatin Cycles on Prognosis for Locally Advanced Cervical Cancer Patients Treated with Concurrent Chemoradiotherapy: A Long-Term Follow-Up, Large Cohort Study
Location: Room 207 B
Presenter: Zheng Zeng, MD – Peking Union Medical College Hospital
123 - Efficacy of Kangfuxin Liquid Retention Enema in Preventing and Treating Radiation-Induced Proctitis in Cervical Cancer Patients: A Randomized, Open-Label, Phase III Study
124 - Evaluating Toxicity and Interaction Outcomes of Systemic Therapy and Stereotactic Ablative Radiotherapy for Oligometastatic Disease: A Secondary Analysis of the Phase II SABR-5 Trial
125 - Impact of Clinical Target Volume Utilization on Outcomes in Patients with Non-Spine Bone Oligometastases Treated with Stereotactic Ablative Radiation Therapy
126 - Real-world implementation of simulation-free radiotherapy (SFRT-1000): A propensity score-matched analysis of 1000 consecutive palliative courses delivered in routine care
Location: Room 151
Presenter: Thilo Schuler, MD, MHInf – Northern Sydney Cancer Centre - Royal North Shore Hospital
3:25 PM – 3:35 PM ET
127 - Applying Deep Learning Based Facial Age Phenotyping to Improve Life Expectancy Prediction in Metastatic Cancer Patients Receiving Palliative Radiotherapy
Location: Room 151
Presenter: Grace Lee, MD – Harvard Radiation Oncology Program
3:35 PM – 3:45 PM ET
128 - Relationship between Cannabis Use and Opioid Use in Patients with Cancer Metastatic to Bone in a Large Multicenter Cohort from a State with Legalized Adult Non-Medical Cannabis
117 - A Prospective Interventional Clinical Trial (MC1732): Characterization of Thoracic Chemoradiotherapy-Related Cardiac Changes Using an Implantable Cardiac Monitor (ICM)
118 - Effectiveness of Nurse-Led Multimodal Rehabilitation for Patients Undergoing Postoperative Radiotherapy of Esophageal Cancer: A Randomized Controlled Trial
120 - Comparing Radiation and Systemic Therapy Patients Longitudinal Satisfaction of a Cloud-Based Bidirectional App Used for Real-Time Communication of Patient-Reported Cancer Treatment Symptoms
150 - Evaluating Neurocognitive Recovery Following Stereotactic Radiosurgery and Whole Brain Radiation Therapy: Insights from a Pooled Analysis of Three Phase III Trials
151 - Neurocognition and Quality of Life for Hypofractionated Stereotactic Radiotherapy (HFSRT) of the Resection Cavity vs. Whole-Brain Radiotherapy (WBRT) Following Brain Metastasis Resection - Results of
Location: Room 147
Presenter: Rami El Shafie, MD – University Medical Center Gottingen (UMG)
5:25 PM – 5:35 PM ET
152 - A Longitudinal Study to Correlate Neurocognitive Changes of IDH-Mutant and IDH-Wildtype Glioma Patients after Chemoradiotherapy with Changes on Resting-State MRI
Location: Room 147
Presenter: Zhihua Liu, PhD – Washington University School of Medicine in St Louis
5:35 PM – 5:45 PM ET
153 - Assessing Atrophy and Neurocognitive Decline in Hippocampal Subfields after Fractionated Brain Radiation Therapy
155 - Novel Statistical-AI Method to Automate Discovery of Predictive Factors and Thresholds for 3 Year Survival, Dysphagia and Xerostomia for Patients with Head and Neck Cancers
158 - Longitudinal CT Feature-Based Model for Predicting Local Recurrence Free Survival in Esophageal Cancer Patients Treated with Definitive Chemoradiotherapy: A Multicenter Study
159 - Explainable MRI-Based Deep Learning Model for Predicting EGFR Mutation in NSCLC Brain Metastases: Advancing Clinical Prognosis and Oncological Treatment Decisions
142 - A Phase II Trial of Camrelizumab in Combination with Concurrent Chemoradiotherapy as First-Line Treatment for Betel Nut-Related Locally Advanced Oral Squamous Cell Carcinoma
143 - Contralateral Neck Recurrence Rates in Head and Neck Carcinomas after Primary Surgery, Bilateral Neck Dissection, a Pathologically Negative Contralateral Neck, and Adjuvant Ipsilateral Neck Radiation
145 - Acupuncture for (Chemo)Radiotherapy - Related Dysphagia in Patients with Head and Neck Squamous Cell Carcinoma (HNSCC): A Randomized Phase 2 Study
147 - Long Term Effects of Cognitive Behavioral Therapy on Late Toxicities, Depressive and Anxiety Symptoms in Patients with Locoregional Advanced Nasopharyngeal Carcinoma Undergoing Chemoradiotherapy: A Ra
Discussant: Christina Henson, MD – University of Oklahoma Health Sciences Center
Monday, September 30, 2024
8:00 AM – 8:10 AM ET
165 - Long-Term Prognostic Analysis of Chemoradiotherapy vs. Chemotherapy after D2 Resection for High-Risk Gastric Cancer: Results from a Prospective Randomized Control Study
173 - Interplay of Radiation and Cyclophosphamide Doses on Local Control in Children with Group III Rhabdomyosarcoma: An Analysis of Studies from the Childrens Oncology Group
180 - Assessing the Tumor Visibility and Respiratory Motion of Liver Cancer Patients on Multi-Task MR and 4D-CT Imaging for Radiation Treatment Planning
Location: Room 152
Presenter: Oi Wai Chau, PhD – Mayo Clinic Alix School of Medicine
10:45 AM – 10:55 AM ET
214 - Transgender and Non-Binary Use of Gender-Affirming Hormone Therapy and Effects on PSA and Prostate Cancer Detection
Location: Room 140
Presenter: Paul Riviere, MD – UCSD Radiation Medicine and Applied Sciences
10:55 AM – 11:05 AM ET
215 - Centering Black Voices: Factors Influencing a Cancer Patients Decision to Join a Clinical Trial
Location: Room 140
Presenter: Charlyn Gomez, BS – University of Maryland School of Medicine
11:05 AM – 11:15 AM ET
216 - Identification of a High-Risk Population in the United States for Anti-EBV Serologic Screening for Nasopharyngeal Carcinoma
218a - Can Radiotherapy Quality Assurance (RT QA) Improve Nasopharyngeal Cancer Outcomes in Low- and Middle-Income Countries (LMICs) - Technical Results of the Second Phase of a Prospective International Ato
181 - Long-Term Patient-Reported Health-Related Quality of Life in the Randomized FORMULA-509 Trial of Salvage Radiotherapy and 6 Months of GnRH Agonist with Either Bicalutamide or Abiraterone Acetate Plus
182 - Quality of Life in Patients Enrolled in a Randomized Clinical Trial Evaluating Hypofractionated Radiotherapy for Intermediate Risk Prostate Cancer
183 - Prospective Evaluation of Supplemental External Beam Radiotherapy in Higher - Risk Prostate Cancer Patients Implanted with Pd-103: Long-Term Results of the 44/20/0 Trials
184 - A Randomized Comparison of Low Dose Rate or High Dose Rate Brachytherapy Combined with External Beam Radiation for Unfavorable Intermediate or High Risk Prostate Cancer: Efficacy Results at Median 6 Y
186 - Randomized Controlled Trial of PSMA-PET Image Guided Intensification of Salvage Radiotherapy after Radical Prostatectomy: Which Patients Are Most Likely to Benefit and Other Secondary Analyses
Location: Room 202
Presenter: Colin Belliveau, MD – Centre Hospitalier de l'Universite de Montreal (CHUM)
11:45 AM – 11:55 AM ET
187 - Combination of Nivolumab Immunotherapy with Radiation Therapy and Androgen Deprivation Therapy in the Management of Gleason Group 5 Prostate Cancer: Final Analysis of a Phase 2 Trial
203 - Defining the Role of Radiotherapy for Indolent, Primary Cutaneous B-Cell Lymphoma - First Results from a Multicenter Registry by the International Lymphoma Radiation Oncology Group (ILROG)
189 - Hypofractionated Radiotherapy plus Concurrent Chemotherapy with or without Consolidation Immunotherapy in Patients with Locally Advanced Non-Small Cell Lung Cancer (GASTO-1052)
Location: Room 207
Presenter: Hui Liu, MD, PhD – Sun Yat-Sen University Cancer Center
11:05 AM – 11:15 AM ET
190 - The Selective Personalized RadioImmunotherapy for Locally Advanced NSCLC Trial (SPRINT): Patient-Reported Outcomes
Location: Room 207
Presenter: Nitin Ohri, MD, MS – Montefiore Einstein Comprehensive Cancer Center
11:15 AM – 11:25 AM ET
191 - Phase II Trial of Risk-Adaptive Chemoradiation for Unresectable Non-Small Cell Lung Cancer: FLARE-RT Mature Outcomes and Patterns of Failure
193 - Durvalumab Combined with Concurrent Chemoradiotherapy in Patients with Limited-Stage Small-Cell Lung Cancer: A Prospective, Single-Arm, Phase II Clinical Trial
Location: Room 207
Presenter: Wen Bin Shen, MD – The Fourth Hospital of Hebei Medical University
11:45 AM – 11:55 AM ET
194 - Simultaneous Integrated Boost vs. Conventional Radiotherapy for Patients with Limited-Stage Small Cell Lung Cancer: A Randomized, Non-Inferiority, Open-Label, Phase 3 Trial
Location: Room 207
Presenter: Tianyou Zhan, MD – National Cancer Center/National Clinical Research Center for Cancer Cancer Hospital, CAMS & PUMC
10:45 AM – 10:55 AM ET
208 - Assessment of Circulating Tumor Cells in Oligometastatic Castration-Sensitive Prostate Cancer Patients from the ORIOLE Trial
211 - Prognostic Implications of Cerebrospinal Fluid Circulating Tumor DNA (CSF ctDNA) Following Radiation Therapy in Patients with Leptomeningeal Metastasis: Analysis of a Randomized Phase II Trial
Discussant: Kent Mouw, MD, PhD – Dana-Farber/Brigham and Women's Cancer Center
10:45 AM – 10:55 AM ET
195 - A Deep Learning-Driven Framework for Large Language Model-Assisted Automatic Target Volume Localization and Delineation for Enhancing Spinal Metastases Stereotactic Body Radiotherapy Workflow
196 - Identifying Candidates for Postoperative Radiotherapy in Patients with Non-Small Lung Cancer: Multicenter Deep Learning Model Development and Prospective Validation
LBA01 - Prostate Advanced Radiation Technologies Investigating Quality of Life (PARTIQoL): Phase III Randomized Clinical Trial of Proton Therapy vs. IMRT for Localized Prostate Cancer
224 - Natural History after Likely Cure vs. Recurrence vs. after ProsTate RadiOtheRapy (RAPTOR): A Pooled Analysis of More than 13000 Patients from 21 Randomized Controlled Trials
236 - "If You're Talking, I Think You're Muted:" Follow-Up Analysis of Weekly Peer Review Discussion and Deviation Detection after Transitioning from Virtual to In-Person Format
Location: Room 209
Presenter: Ryan Hughes, MD – Wake Forest University School of Medicine
3:00 PM – 3:10 PM ET
225 - Early Clinical Insights into FDG-Guided Radiotherapy Planning and Delivery on a Novel PET-Linac Platform in Patients with Lung and Bone Lesions: Pioneering Real-Time Biology-Guided Radiotherapy
Location: Room 145
Presenter: Bin Cai, PhD – University of Texas Southwestern Medical Center
3:10 PM – 3:20 PM ET
226 - Toward Adaptive Dose Painting with Hypoxia Biomarkers: Feasibility of Oxygen-Enhanced (OE)-MRI T1 Mapping on Low-Field MR-Linac
227 - Pathologic Response Prediction Value of 18f-Fapi PET/CT in ESCC Treated with Neoadjuvant Camrelizumab and Chemotherapy: A Phase II Clinical Trial
238 - Single-Institution Phase 1/2 Prospective Trial Evaluating Three-Fraction Partial Breast Irradiation: Four Year Outcomes Including Quantitative Cosmesis and Patient-Reported Outcomes
Location: Room 202
Presenter: Silpa Raju, MD – Washington University in St. Louis
5:20 PM – 5:30 PM ET
239 - Clinical Outcomes of Patients with Early-Stage Breast Cancer Treated with Five-Fraction Partial Breast Irradiation vs. Intraoperative Radiation Therapy
240 - Long-Term Results of a Phase II Prospective Clinical Trial of Single-Fraction, High-Gradient Adjuvant Partial Breast Irradiation in Early-Stage, Hormone Sensitive Breast Cancer
Location: Room 202
Presenter: David Lakomy, MD – Washington University in St. Louis
5:40 PM – 5:50 PM ET
241 - Comparison of Acute and Late Toxicities with Daily vs. Every Other Day Five Fraction Partial Breast Radiation Therapy
255 - Initial Results of the Multicenter Phase II Trial of a Novel Hypofractionated Low-Dose Radiotherapy for Indolent Non-Hodgkin Lymphoma
Location: Room 144
Presenter: Xinyue Wang, MD – Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
5:40 PM – 5:50 PM ET
256 - A Proof-of-Principle Study of Split-Course Bridging Radiotherapy (SC-BRT) prior to Commercial CAR T-Cell Therapies for Relapsed or Refractory B-Cell Lymphomas: Results from Phase 1a Pilot Cohort
242 - Long-Term Outcomes of Postoperative Radiotherapy for Patients with pIIIA-N2 Non-Small Cell Lung Cancer after Complete Resection and Adjuvant Chemotherapy: The Phase 3 PORT-C Randomized Clinical Trial
243 - Long-Term Outcomes of a Prospective Randomized Trial of Passive Scattering Proton Therapy vs. Intensity-Modulated Photon Radiotherapy for Locally Advanced Non-Small-Cell Lung Cancer
244 - The Impact of Prophylactic Bisphosphonates on Radiation-Induced Rib Fractures and Chest Wall Pain in Peripheral Lung Tumor SBRT: A Randomized, Double-Blind, Placebo-Controlled Study
246 - Exploratory Analysis of ctDNA and Imaging Response in the Phase I/II CHORUS Study of Canakinumab with Chemoradiation and Durvalumab Consolidation for Stage III NSCLC
247 - A Phase II Trial of 5-Day Neoadjuvant Radiation Therapy for Patients with High-Risk Primary Soft Tissue Sarcoma: Long-Term Follow-Up and Outcomes
248 - The Impact of Hypofractionated Pre-Operative Radiation Therapy on PD-L1 Expression in Soft Tissue Sarcomas
Location: Room 143
Presenter: Manpreet Bedi, MD, MS – Medical College of Wisconsin Affiliated Hospitals
5:20 PM – 5:30 PM ET
249 - Habitat Escalated Adaptive Therapy (HEAT): A Phase 2 Trial Utilizing Radiomic Habitat-Directed and Genomic-Adjusted Radiation Dose (GARD) Optimization for High-Grade Soft Tissue Sarcoma
Location: Room 143
Presenter: Arash Naghavi, MD, MS – H. Lee Moffitt Cancer Center and Research Institute
5:30 PM – 5:40 PM ET
250 - Reduction of Bone Fracture after Radiotherapy in Lower Extremity Soft Tissue Sarcoma after Implementing Bone Avoidance Objectives for Radiotherapy Planning
251 - Immune Profiling of "Radvax" Abscopal Responses in Metastatic Melanoma Patients Progressing on Anti-PD1 Therapy Treated with Hypofractionated Radiotherapy (HFRT) to One Lesion Combined with Pembrolizu
Location: Room 143
Presenter: John Lukens, MD – Hospital of the University of Pennsylvania
1018 - Dose-Escalated Hypofractionated Adaptive Radiotherapy (DEHART) and 60 Gy in 15 Fractions for Advanced Head and Neck Cancers: An Interim Analysis of a Phase I Trial
1021 - Prognostic Value of Image-Identified Extranodal Extension and Potential Role in Cn Classification in HPV-Negative Oropharyngeal Cancer: A Multi-Center Cohort Study
1023 - Treatment Response-Adapted Risk Index Model for Survival Prediction and Adjuvant Chemotherapy Selection in Nonmetastatic Nasopharyngeal Carcinoma
Location: Room 152
Presenter: Yang Liu, MD – Cancer Hospital Chinese Academy of Medical Sciences
5:35 PM – 5:55 PM ET
Questions and Answers
Location: Room 152
5:55 PM – 6:00 PM ET
Closing
Location: Room 152
5:00 PM – 5:05 PM ET
Introduction
Location: Room 147
5:05 PM – 5:10 PM ET
1024 - CT-Guided Online Adaptive Stereotactic Body Radiation Therapy for Liver Tumors
258 - Exploratory Analysis of Plasma Protein Abundance Kinetics from I-SABR, A Randomized Phase II Trial of Stereotactic Ablative Radiotherapy with or without Nivolumab in Stage I-IIA or Recurrent Non-Small
1044 - TEAMRO: Final Analysis of TEAMRO (TEAching Mentorship in Radiation Oncology), A Multicenter Prospective Phase 2 Intervention Study on Teaching Mentorship Skills to Resident Physicians Working with Med
Location: Room 158
Presenter: Anurag Saraf, MD – Brigham and Women's Hospital/Dana-Farber
8:20 AM – 8:25 AM ET
1045 - Patterns of Contouring Mistakes in the Novice Resident: A Qualitative Analysis to Guide Future Educational Efforts
1047 - Optimizing Leadership Development Strategies for Enhanced Leader and Team Impact
Location: Room 158
Presenter: Amanda Woods, PhD – The University of Texas MD Anderson Cancer Center
8:35 AM – 8:55 AM ET
Questions and Answers
Location: Room 158
8:55 AM – 9:00 AM ET
Closing
Location: Room 158
8:00 AM – 8:05 AM ET
Introduction
Location: Room 140
8:05 AM – 8:10 AM ET
1037 - ctDNA Predicts Pain Response in a Multi-Institutional Phase II Trial of Palliative Radiation, Palbociclib and Hormone Therapy in Metastatic Breast Cancer
1038 - Final Report of a Phase I/II Study of BMS-986156 (Glucocorticoid-Induced TNFR-Related Gene [GITR] Agonist) with Ipilimumab or Nivolumab with/without Stereotactic Ablative Radiotherapy in Patients with
Location: Room 140
Presenter: Xinyan Xu, MD – MD Anderson Cancer Center
8:20 AM – 8:25 AM ET
1039 - Identifying Patients with Bone Metastases at Highest Risk of Skeletal-Related Events and Understanding Underuse of Bone Modifying Agents: A Retrospective Analysis
1040 - Development of Nomograms to Predict Polymetastatic Progression Free Survival and Overall Survival in Patients Treated with Stereotactic Ablative Radiotherapy for Oligometastatic or Oligoprogressive Ca
Location: Room 140
Presenter: Subhadip Das, MD – BC Cancer Surrey and University of British Columbia
8:30 AM – 8:35 AM ET
1041 - Progress in Shortening Treatment Courses for Bone Metastases in a Statewide Quality Consortium
1031 - Using Virtual Monoenergetic Images and Electron Density (Rho) Images from Photon-Counting CT (PCCT) for Radiation Therapy (RT) Dose Calculation: A Comparison Study
Location: Room 152
Presenter: Xin Wu, MS – Duke University Medical Center
8:15 AM – 8:20 AM ET
1032 - Comparison of Enhanced Cone-Beam CT Using Next Generation Reconstruction with Deep Learning-Based Synthetic CT for Adaptive Radiotherapy in Pelvic Cancers
277 - The Association of Left Anterior Descending Coronary Artery Radiation Dose with Major Adverse Cardiac Events Following Modern Breast Radiotherapy
279 - Safety and Efficacy of Combined Trastuzumab-Deruxtecan and Concurrent Radiation Therapy in Breast Cancer: The TENDANCE Multicentric French Study (Trastuzumab-Deruxtecan and Concurrent Radiation Therap
Location: Room 207
Presenter: Kamel Debbi, MD – Henri Mondor University Hospital and Faculte de Medecin de Creteil Paris XII
1:15 PM – 1:25 PM ET
280 - Characterization of Skin Microbiome Profile before and during Radiation Therapy and Its Correlation to the Occurrence and Severity of Radiation Dermatitis
281 - A Phase I/II Trial of Spectrophotometric Skin Changes during and after Radiotherapy and Correlation with Radiation-Induced Skin Toxicity in Breast Cancer Patients with Skin of Color
Location: Room 207
Presenter: Juhi Purswani, MD – New York University School of Medicine
1:35 PM – 1:45 PM ET
282 - Analysis of Rib Fracture Risk after Breast Radiation with Various Dose Fractionations
Location: Room 207
Presenter: Jackson Howell, MD – University of Utah Huntsman Cancer Institute
283 - Measuring the Integration of Stereotactic Ablative Radiotherapy plus Surgery for Early-Stage Non-Small Cell Lung Cancer (MISSILE): Long-Term Clinical Outcomes
Location: Room 147
Presenter: Vivian Tan, MD – London Health Sciences Centre
12:55 PM – 1:05 PM ET
284 - A Phase II Randomized Trial of Radical Resection vs. Stereotactic Body Radiation Therapy (SBRT) in Patients with Operable Stage I Non-Small Cell Lung Cancer (NSCLC): Final Report Of RTOG-F3502
286 - Dosimetric Outcomes of SBRT to Ultracentral Lung Tumors: Lessons from the SUNSET Trial
Location: Room 147
Presenter: Rohan Salunkhe, MD, MBBS – Princess Margaret Cancer Center, University Health Network
1:25 PM – 1:35 PM ET
287 - Accelerated Hypofractionated Chemoradiation Followed by Stereotactic Ablative Radiotherapy Boost for Locally Advanced, Unresectable Non-Small Cell Lung Cancer: Final Results from a Nonrandomized Contr
288 - A Phase I Study of Cyclical Hypofractionated Palliative Radiation (Quad Shot) for Lung Tumors in Patients with Stage IV Non-Small Cell Lung Cancer (NSCLC): Results from the PROMISE 006 Trial
Location: Room 147
Presenter: Helen Zhang, MD – Memorial Sloan Kettering Cancer Center
272 - Impact of Organ-at-Risk (OAR) Radiation Dosimetry on Acute and Late Toxicity after Prostate Stereotactic Body Radiation Therapy (SBRT): A Post-Hoc Analysis of a Phase III Randomized Clinical Trial of
273 - Redefining Breast Cancer Tumor Size Classification through Big Data Analytics: A New Approach to Enhancing Prognostic Accuracy and Personalized Treatment
Location: Room 152
Presenter: Bin Feng, MS, BS – Chongqing University Cancer Hospital
1:25 PM – 1:35 PM ET
274 - Evaluation of Immune System Plasticity with a Multi-Compartment Model of Immuno-Positron Emission Tomography
1048 - Bridging Prediction and Causality: Deciphering Clinical Outcomes in Locally Advanced Non-Small Cell Lung Cancer Treated with Chemoradiation via Multitask Machine Learning and Causal Inference of Proto
1052 - Predicting Pulmonary Toxicity in Lung Cancer Patients with Interstitial Lung Disease Receiving SABR Using Machine Learning: A Secondary Analysis of ASPIRE-ILD
1067 - Evaluation of Genomic and Pathologic Features Associated with Outcomes among Patients with Sentinel Lymph Node-Positive Melanoma in the Contemporary Era
1069 - Preoperative Hypofractionated Radiotherapy with Locoregional Hyperthermia in Recurrent and Radiation-Associated Sarcomas: Final Results of a Phase 2 Clinical Trial
Location: Room 151
Presenter: Mateusz SpaÅ‚ek, MD, DSc, PhD, MBA – Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie – Panstwowy Instytut Badawczy w Warszawie
2:55 PM – 3:00 PM ET
1070 - Long-Term Outcomes following Proton-Based Radiation Therapy for Pediatric Chordomas and Chondrosarcomas of the Mobile Spine and the Sacrum
1065 - Use of the 40-Gene Expression Profile (40-GEP) Test to Identify Immune Suppressed Patients with Brigham and Womens Hospital (BWH) T1-T2a Cutaneous Squamous Cell Carcinoma (cSCC) at Higher Risk of Meta
304 - Phase II Trial of Organ Preservation Program Using Short-Course Radiation and Folfoxiri for Rectal Cancer (SHORT-FOX): Clinical Response Outcomes
Discussant: Emma Holliday, MD – The University of Texas MD Anderson Cancer Center
2:30 PM – 2:40 PM ET
296 - Induction Chemotherapy plus Concurrent Chemoradiotherapy vs. Concurrent Chemoradiotherapy Alone in High-Risk Locally Advanced Cervical Carcinoma: A Phase 2, Multicenter, Randomized Controlled Trial
Location: Room 209
Presenter: Hua Yang, MD – The First Affiliated Hospital of Air Force Medical University
2:40 PM – 2:50 PM ET
297 - Comparison of Image-Guided Intensity Modulated Radiotherapy (IG-IMRT) vs. Conventional Radiotherapy (4FRT) for Locoregionally Advanced Cervical Cancer on the NRG GY006 Trial
298 - IMMUNOCERV Phase II Trial Combining the HPV-Specific T Cell Immunotherapy PDS0101 with Chemoradiation for Treatment of Locally Advanced Cervical Cancer
300 - Comparison of Docetaxel and Cisplatin Concurrent and Short-Course Adjuvant Chemotherapy with Cisplatin Concurrent Chemotherapy in Radiotherapy for Locally Advanced Cervical Cancer: A Phase III Multice
LBA08 - Outcomes and Immune Responses from INNATE: A Randomized Phase II Trial of Sotigalimab Immunotherapy during Neoadjuvant Therapy of Rectal Cancer
LBA11 - A Phase II Single Arm Trial of Elective Volume Adjusted De-Escalation Radiotherapy (EVADER) in Patients with Low-risk HPV-related Oropharyngeal Squamous Cell Carcinoma
LBA12 - Radiotherapy Target Volume Delineation Based on Post-Induction Chemotherapy Gross Tumor Volume vs. Pre-induction Volume for Locoregionally Advanced Nasopharyngeal Carcinoma: An Open-Label, Non-Inferio
LBA13 - Safety Profile of Durvalumab (D) as Consolidation Treatment (tx) in Limited-Stage Small-Cell Lung Cancer (LS-SCLC) in ADRIATIC: Focus on Pneumonitis and Immune-Mediated Adverse Events (imAEs)
LBA14 - Neurocognitive Outcome of Conformal Whole Brain Radiotherapy with Bilateral or Unilateral Hippocampal Avoidance Plus Memantine for Brain Metastases: A Phase II Single Blind Randomized Trial
308 - Phase I/II Prospective Dose Escalation Trial with Proton-Based Radiation Therapy for Chordomas and Chondrosarcomas of the Skull Base and Cervical Spine: Long-Term Results from Proton Radiation Oncolog
317 - Magnetic Resonance Imaging-Guided vs. Computed Tomography-Guided Stereotactic Body Radiotherapy for Prostate Cancer: 2-Year Outcomes from the MIRAGE Randomized Clinical Trial
318 - Volumetric Changes and Acute Toxicity with 68Ga Prostate-Specific Membrane Antigen vs 18F-Fluciclovine PET/CT Guided Post-Prostatectomy Radiation: Final Analysis of a Randomized Trial
319 - Dose Escalated Pelvic Lymph Node Intensity Modulated Radiation Therapy (IMRT) with a Simultaneous Hypofractionated Boost to the Prostate for NCCN Very-High Risk Adenocarcinoma of the Prostate, a Prosp
Location: Room 202
Presenter: William Hall, MD – Medical College of Wisconsin (MCW)
4:30 PM – 4:40 PM ET
320 - Initial Results of a Multi-Institutional Phase 1/2 Trial of Focal Dose-Escalated Salvage High Dose Rate Brachytherapy for Radiorecurrent Prostate Cancer (F-SHARP)
321 - Focal MR-Guided HDR Brachytherapy Boost Combined with SBRT for Localized Prostate Cancer
Location: Room 202
Presenter: Carlton Johnny, MD – Princess Margaret Cancer Center, University Health Network
4:50 PM – 5:00 PM ET
322 - Stereotactic Body Radiotherapy (SBRT) vs. Conventional Fractionation External Beam Radiotherapy (EBRT) Boost for Unfavorable Intermediate and High-Risk Prostate Cancer; Early Results of PBS: A Phase I
312 - Phase II Study of Radiation Volume and Dose De-Intensification Following Tors and Neck Dissection for p16+ Oropharyngeal Squamous Cell Carcinoma - Long-Term Results of Expanded Cohort
Location: Room 145
Presenter: John Lukens, MD – Hospital of the University of Pennsylvania
4:10 PM – 4:20 PM ET
313 - Quality of Life (QOL) of Patients with Human Papillomavirus (HPV)-Associated Oropharyngeal Squamous Cell Carcinoma (OPSCC) in NRG-HN002
315 - HPV-Seq is Prognostic in p16-Positive Oropharyngeal Cancer (OPC): Independent Validation on a Large Prospective Cohort and a Secondary Analysis of NRG-HN002
316 - The Preliminary Analysis of Circulating Human Papillomavirus DNA in a Phase III Trial of Concurrent Chemoradiation (CRT) with Intensity Modulated Proton Therapy (IMPT) vs. IMRT in Oropharyngeal Squamo
1072 - Sequential 90Y Selective Internal Radiation Therapy (SIRT) and Stereotactic Body Radiation Therapy (SBRT) Using 90Y PET-Based Absorbed Dose Maps: Interim Analysis of a Phase I St
1073 - Comprehensive Geriatric Assessment Guided Radiotherapy in Older Patients with Locally Advanced Rectal Cancer - Results of a Multicenter Prospective Non-Operative Cohort Study
Location: Room 152
Presenter: Yuexin Yang, MD – Chinese Academy of Medical Sciences Cancer Hospital Shenzhen Hospital
4:20 PM – 4:25 PM ET
1074 - Long-Term Outcomes of Definitive Chemoradiation with Proton Therapy for Treatment of Carcinoma of the Anal Canal: Combined Analysis of Two Prospective Trials
Location: Room 152
Presenter: Grace Lee, MD – Harvard Radiation Oncology Program
4:25 PM – 4:30 PM ET
1075 - Patient Reported Outcomes after Chemoradiation with IMPT vs. IMRT for Patients with Anal Canal Squamous Cell Carcinoma
1083 - Outcome and Pattern of Failure Following Definitive High-Dose Radiotherapy for PrImary Vulvar CancEr: Interim Analysis of The DRIVE Multicenter Cohort Study
1086 - Outcomes of Radiotherapy in the First-Line Treatment of Recurrent/Metastatic Cervical Cancer: A Multicenter, Retrospective Study
Location: Room 204
Presenter: Peng Xie – Shandong Cancer Hospital and Institute
4:25 PM – 4:30 PM ET
1087 - A Retrospective Comparison of Acute Toxicities in Patients Receiving Pelvic Radiation for Newly Diagnosed Gynecologic Primaries with Intensity Modulated Proton Therapy and Volume Modulated Arc Therapy
Location: Room 204
Presenter: Matthew Brown, MD – University of Maryland Radiation Oncology
4:30 PM – 4:35 PM ET
1088 - The Evaluation of Anxiety and Pain Levels in Patients Receiving Brachytherapy: Turkish Society For Radiation Oncology Brachytherapy Group Study (Brg-001)
Location: Room 204
Presenter: Ferah Yildiz, MD – Hacettepe University Medical School
4:35 PM – 4:55 PM ET
Questions and Answers
Location: Room 204
4:55 PM – 5:00 PM ET
Closing
Location: Room 204
4:00 PM – 4:05 PM ET
Introduction
Location: Room 209
4:05 PM – 4:10 PM ET
1077 - Routine Physics Work Efficacy and Efficiency Improvement with Duty Shared Among Daily Physicist Group for a Multi Hospital Radiation Oncology Network
1079 - Automatic Large-Scale Prospective Monitoring and Blind Evaluation of the Performance of Commercial AI Auto-Segmentation in Routine Clinical Practice: Preliminary Results for a Cohort of Breast Cancer
1082 - Impact of Standardized Structure Templates on Violations for Radiation Plans Submitted to Co-Operative Group Clinical Trials
Location: Room 209
Presenter: Gobind Gill, MD – University of Alabama at Birmingham
4:35 PM – 4:55 PM ET
Questions and Answers
Location: Room 209
4:55 PM – 5:00 PM ET
Closing
Location: Room 209
5:15 PM – 5:25 PM ET
328 - Cellular Immune and Genomic Biomarkers in NRG-HN003, a Phase I Study Adding Pembrolizumab to Adjuvant Cisplatin and Radiation Therapy (CRT) in Pathologically High-Risk Head and Neck Cancer (HNSCC)
Location: Room 146
Presenter: Julie Bauman, MD – George Washington University Cancer Center
5:25 PM – 5:35 PM ET
329 - Metrics Derived from Architecture of Tumor-Infiltrating Lymphocytes are Associated with Overall Survival in HPV-Positive Oropharyngeal Squamous Cell Carcinoma Patients: Results from NRG/RTOG 0129 and
330 - Tumor Hypoxia on 18F-Fluoromisonidazole Positive Emission Tomography as a Predictor of Distant Metastasis-Free Survival after Chemoradiation for Head and Neck Squamous Cell Carcinoma: A Pooled Analysi
332 - Chromosomal Instability as a Prognostic Biomarker for Local Failure in Laryngeal Carcinoma Patients Treated with Definitive Radiation in NRG/RTOG 9512
1091 - Characterization of Focal Leptomeningeal Disease among Patients with Brain Metastases: A Novel Entity
Location: Room 151
Presenter: Nayan Lamba, MD – Harvard Radiation Oncology Program
5:35 PM – 5:40 PM ET
1092 - Pre-Operative vs. Post-Operative Fractionated Stereotactic Radiotherapy: A Single-Institution Analysis of 534 Resected Metastases
Location: Room 151
Presenter: Haley Perlow, MD – Case Western Reserve University/University Hospitals Cleveland Medical Center
5:40 PM – 5:45 PM ET
1093 - Maximum Tolerated Dose of Neoadjuvant Stereotactic Radiosurgery and Post-Treatment Immune Profiling for Metastatic Brain Tumors: Results of a Phase I Dose Escalation Trial
1094 - Multi-Center Phase I Study of Concurrent Paxalisib and Radiation Therapy in Patients with Solid Tumor Brain Metastases (BM) or Leptomeningeal Metastases (LM) Harboring PI3K Pathway Mutations
1096 - Automated Segmentation of Pancreatic Tumor Microvasculature in High-Resolution Optical Coherence Tomography (OCT) Using Pre-Trained Large-Scale Supervised Networks for Early Evaluation of Radiation Th
1099 - The Novel Assessment of Stereotactic Body Radiotherapy (SBRT) for Cardiac Radioablation to the Cavotricuspid Isthmus by 13C Pyruvate Metabolic Imaging and Redox Reaction Imaging Using Dynamic Nuclear
1100 - Orthogonal 2D MR Imaging and Manifold Learning Enables Real-Time 3D Tumor Tracking
Location: Room 147
Presenter: John Ginn, PhD – Duke University School of Medicine
6:10 PM – 6:15 PM ET
Closing
Location: Room 147
Wednesday, October 2, 2024
8:00 AM – 8:10 AM ET
334 - Validation of a Digital Pathology-Based Multimodal Artificial Intelligence Model in Oliogmetastatic Castration-Sensitive Prostate Cancer, including in Patients from the STOMP and ORIOLE Phase II Rando
Location: Room 207
Presenter: Philip Sutera, MD – Johns Hopkins Radiation Oncology Kimmel Cancer Center
8:10 AM – 8:20 AM ET
333 - A Digital Pathology Multimodal Artificial Intelligence Algorithm is Associated with Pro-Metastatic Genomic Pathways in Oligometastatic Prostate Cancer
335 - A Validation Study on the Impact of Decipher® Testing on Treatment Recommendations in African American and Non-African American Men with Prostate Cancer (VANDAAM STUDY)
Location: Room 207
Presenter: Kosj Yamoah, MD, PhD – H. Lee Moffitt Cancer Center and Research Institute
8:30 AM – 8:40 AM ET
336 - Examination of Decipher Prostate Genomic Classifier in Patients with De Novo Metastatic Disease from a Large Scale Real-World Clinical and Transcriptomic Data Linkage
1109 - A Novel Comprehensive Multi-Omic Biosignature to Assess Recurrence Risk and Adjuvant Therapy Benefit in Early-Stage Hormone-Positive Invasive Breast Cancer Patients
1111 - Pre-Operative Boost Results in Low Rates of Re-Excision and Reduced Time from Initial Diagnosis to Completion of Local-Regional Treatment in Breast Cancer Patients
1119 - Normalization of Lactate Dehydrogenase (LDH) as a Potential Prognostic Factor for Relapsed/Refractory Aggressive B-Cell Lymphoma (R/R BCL) Patients Receiving CAR T Following Bridging Radiotherapy: Res
1113 - Applying GD-EOB-DTPA Enhanced MR to Unveil the Radiobiological Effect of Proton and Photon Therapy Based on the Longitudinal Evolution of the Focal Liver Reaction
1115 - Plan-Specific Range Tolerance Method for CBCT Triggered Adaptive Plans in Intensity Modulated Proton Therapy: Pilot Study on Head and Neck
Location: Room 147
Presenter: Weiguang Yao, PhD – University of Maryland School of Medicine, Baltimore
8:20 AM – 8:25 AM ET
1116 - Assessing Dose Uncertainties in Cardiac SBRT due to Cardiorespiratory Motion: Photon vs. Proton Therapy Comparison
Location: Room 147
Presenter: Guangjun Li, PhD – West China Hospital of Sichuan University
8:25 AM – 8:30 AM ET
1117 - A New RBE Optimization Method with Iterative Jacobian-Based Linearization for Carbon Ion Radiation Therapy
Location: Room 147
Presenter: Chao Wang, PhD – University of Kansas Medical Center
8:30 AM – 8:35 AM ET
1118 - Split Field IMPT Optimization to Maximize OAR Dose Rate and Implications for the Minimal FLASH Effect
Location: Room 147
Presenter: Ke Sheng, PhD – University of California, San Francisco
8:35 AM – 8:55 AM ET
Questions and Answers
Location: Room 147
8:55 AM – 9:00 AM ET
Closing
Location: Room 147
8:00 AM – 8:05 AM ET
Introduction
Location: Room 145
8:05 AM – 8:10 AM ET
1125 - Assessing the Feasibility and Dosimetric Impact of a Non-Animal Stabilized Hyaluronic Acid (NASHA) Rectal Spacer in High-Dose-Rate Brachytherapy for Prostate Cancer
Location: Room 145
Presenter: Reema Patel, BS – University of Virginia School of Medicine
8:10 AM – 8:15 AM ET
1126 - CT Dosimetry in Radioembolization: Image Acquisition Considerations
1129 - A Multi-Center Study on the Clinical Deliverability of Fully Automated Planning for Stereotactic Body Radiation Therapy in Lung Cancer Using a Deep Learning Transfer Method
1131 - Macropathology and Multimodal Magnetic Resonance Image Based Deep Learning Model for Personalized Definition of Target Volume in Patients with Glioma
1135 - Analysis of Late Cognitive Outcomes after Whole Brain Radiotherapy and Radiosurgery for Brain Metastases in the North Central Cancer Treatment Group (NCCTG) N0574 and N107C Clinical Trials
352 - The Effect of Tumor Biological Effective Dose (BED) on Stereotactic Body Radiotherapy (SBRT) Outcomes for Locally Advanced Cholangiocarcinoma (CCA): An Analysis of the ABC-07 Randomized Trial
353 - Safety and Efficacy Results of a Phase II Clinical Trial Evaluating Moderately-Hypofractionated Chemoradiotherapy for Pancreatic Ductal Adenocarcinoma
1144 - Development of Prediction Model for Right and Left Liver Hypertrophy to Estimate Response in Patients Treatments Simulated with Photon Based 3DCRT and IMRT Plans
1148 - General and Organ Specific Consensus Recommendations for Stereotactic Body Radiotherapy Dose Prescription according to ICRU Report 91 from Working Groups on Stereotactic Radiotherapy
1158 - Optimizing Target and Diaphragmatic Configuration, and Dosimetric Benefits Using Continuous Positive Airway Pressure (CPAP) in Stereotactic Ablative Radiotherapy for Lung Tumors
Location: Room 143
Presenter: Jung Bin Park, MD – Seoul National University College of Medicine
12:55 PM – 1:00 PM ET
1159 - Addressing the Impact of Skin Pigmentation on Quantitative Cherenkov Dosimetry in the First Diverse Patient Imaging Study
1160 - Efficacy of Thermoplastic Mask Heating before Radiotherapy in Reducing Setup Error for Patients with Gynecological Tumor: A Randomized Controlled Study